Vertex Announces FDA Approval for Expanded Use of Casgevy for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Дата публикации: 01-07-2026 23:07:52

BOSTON--(BUSINESS WIRE)--Jul. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of Casgevy (exagamglogene autotemcel) for the treatment of people...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA одобрило генную терапию серповидноклеточной анемии у детей с двух лет	7	8	03-07-2026
2	FDA Approves Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease	0	18.73	26-06-2026
3	Octapharma USA Announces Expanded FDA Approval of Wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years	0	14.08	08-07-2026
4	FDA Grants Accelerated Approval for Trutakna (atacicept-vymj) for Adult Patients with Primary IgA Nephropathy	0	17.01	07-07-2026
5	PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera	0	13.23	26-06-2026
6	FDA approves gene therapy for children with sickle cell disease ages 2+	5	7	09-07-2026
7	FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer	0	18.09	14-07-2026
8	FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva	0	15.91	19-08-2026
9	FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma	0	11.39	13-08-2026
10	FORUS Therapeutics Inc – Announces Health Canada Approval of BESREMI® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)	0	15.22	06-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.35. Источник: www.drugs.com.